A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens (Q82758717)
scientific article published on 02 February 2010
Language:
(P31) (Q13442814)
(P50) (Q83677686)
(P304) 1021-1028
(P407) (Q1860)
(P433) 5
(P478) 29
(P577) Tuesday, February 2, 2010
(P921) (Q188874)
(Q974135)
(Q25493920)
(Q420207)
(P1433) (Q2312231)
(P1476) "A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens" (language: en)
(P2093) Jaafar Bennouna
Istvan Lang
Manuel Valladares-Ayerbes
Katalin Boer
Antoine Adenis
Pilar Escudero
Tae-You Kim
Gillian M Pover
Clive D Morris
(P2860) (Q40385205)
(Q37287048)
(Q40093939)
(Q34519158)
(Q58614884)
(Q27851426)
(Q35677127)
(Q34514696)
(Q40164535)
(Q45041047)
(Q34429990)
(Q34595700)
(Q36907524)
(Q46542857)
other details
description scientific article published on 02 February 2010

External Links